Teva announces FDA approval of UZEDY extended-release injectable suspension

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and MedinCell announced that the U.S. Food and Drug Administration has approved UZEDY, or risperidone, extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq, a copolymer technology proprietary to MedinCell that controls the steady release of risperidone. Therapeutic blood concentrations are reached within 6-24 hours of a single dose. UZEDY will be available in the U.S. in the coming weeks.